Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

BMRN

Biomarin Pharmaceutical Inc.

Apr 23 • 04:00PM ET

92.06

Dollar change +2.57
Percentage change 2.87	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VO VXF VUG IBB VOT USMV VHT IWR SCHM

Index	-	P/E	105.67	EPS (ttm)	0.87	Insider Own	2.03%	Shs Outstand	188.60M	Perf Week	1.31%
Market Cap	17.47B	Forward P/E	35.21	EPS next Y	2.61	Insider Trans	-4.53%	Shs Float	185.93M	Perf Month	8.14%
Income	167.65M	PEG	2.46	EPS next Q	0.32	Inst Own	98.75%	Short Float	1.65%	Perf Quarter	-1.05%
Sales	2.42B	P/S	7.22	EPS this Y	76.86%	Inst Trans	2.04%	Short Ratio	2.18	Perf Half Y	12.12%
Book/sh	26.25	P/B	3.51	EPS next Y	69.94%	ROA	2.54%	Short Interest	3.06M	Perf Year	-5.59%
Cash/sh	5.66	P/C	16.27	EPS next 5Y	43.00%	ROE	3.51%	52W Range	76.02 - 99.56	Perf YTD	-4.52%
Dividend Est.	-	P/FCF	279.23	EPS past 5Y	-	ROI	3.00%	52W High	-7.53%	Beta	0.31
Dividend TTM	-	Quick Ratio	1.57	Sales past 5Y	10.23%	Gross Margin	76.15%	52W Low	21.10%	ATR (14)	1.78
Dividend Ex-Date	-	Current Ratio	2.51	EPS Y/Y TTM	16.20%	Oper. Margin	8.01%	RSI (14)	63.40	Volatility	1.80% 1.90%
Employees	3401	Debt/Eq	0.23	Sales Y/Y TTM	18.16%	Profit Margin	6.93%	Recom	1.73	Target Price	110.19
Option/Short	Yes / Yes	LT Debt/Eq	0.13	EPS Q/Q	8269.23%	Payout	0.00%	Rel Volume	0.92	Prev Close	89.49
Sales Surprise	1.16%	EPS Surprise	-43.73%	Sales Q/Q	25.23%	Earnings	Apr 24 AMC	Avg Volume	1.41M	Price	92.06
SMA20	3.68%	SMA50	5.03%	SMA200	3.40%	Trades		Volume	1,298,900	Change	2.87%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-15-23	Initiated	Wells Fargo	Overweight	$100
Oct-23-23	Upgrade	Bernstein	Underperform → Mkt Perform	$82
Sep-28-23	Initiated	Raymond James	Mkt Perform
Sep-18-23	Initiated	UBS	Buy	$120
Jul-27-23	Initiated	Scotiabank	Sector Perform	$95
Jul-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$102
Jun-14-23	Resumed	Credit Suisse	Outperform	$120
Mar-21-23	Initiated	Bernstein	Underperform	$81
Feb-22-23	Downgrade	Oppenheimer	Outperform → Perform
Feb-21-23	Initiated	Citigroup	Neutral	$116
Jan-30-23	Initiated	BMO Capital Markets	Market Perform	$107
Jan-18-23	Initiated	Canaccord Genuity	Hold	$119
Oct-31-22	Upgrade	Oppenheimer	Perform → Outperform	$92 → $110
Jul-13-22	Initiated	Cantor Fitzgerald	Overweight	$110
Jun-13-22	Resumed	Wedbush	Neutral	$146 → $70
Apr-25-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$96 → $113
Nov-22-21	Upgrade	William Blair	Mkt Perform → Outperform
Oct-07-21	Resumed	Jefferies	Buy	$100
Sep-09-21	Upgrade	Stifel	Hold → Buy	$86 → $96
Jun-04-21	Resumed	Robert W. Baird	Outperform	$101

Show Previous Ratings

Apr-23-24 11:36AM	Is a Surprise Coming for BioMarin (BMRN) This Earnings Season? (Zacks)
Apr-22-24 04:26PM	BioMarin Pharmaceutical Investors to Focus Q1 on Strategic Review, Cost-Cutting Measures, UBS Says (MT Newswires)
09:16AM	Gear Up for BioMarin (BMRN) Q1 Earnings: Wall Street Estimates for Key Metrics (Zacks)
Apr-17-24 10:01AM	BioMarin Pharmaceutical (BMRN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-12-24 07:00PM	Insider Sell: Biomarin Pharmaceutical Inc (BMRN) Chief Accounting Officer Erin Burkhart ... (GuruFocus.com)
08:00AM	Loading…
Apr-10-24 08:00AM	BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET (PR Newswire)
Apr-01-24 07:01PM	Insider Sell: EVP, Chief Legal Officer George Davis Sells 24,602 Shares of Biomarin ... (GuruFocus.com)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-16-24 05:06AM	4 Extraordinary Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market (Motley Fool)
Mar-12-24 08:30AM	New Data to be Presented for BioMarin's VOXZOGO (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting (PR Newswire)
Mar-11-24 10:00AM	BioMarin Pharmaceutical: Pioneering Innovations Are Driving Future Growth (GuruFocus.com)
Mar-08-24 01:31AM	Insider Sell: President, Worldwide R&D Henry Fuchs Sells 35,341 Shares of Biomarin ... (GuruFocus.com)
Mar-07-24 08:30AM	BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer (PR Newswire)
Mar-01-24 09:00AM	BioMarin Scheduled to Participate in March Investor Conferences (PR Newswire)
Feb-27-24 12:03AM	Decoding Biomarin Pharmaceutical Inc (BMRN): A Strategic SWOT Insight (GuruFocus.com)
02:36PM	Loading…
Feb-26-24 02:36PM	REFILE-UPDATE 2-BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies (Reuters)
02:12PM	REFILE-BioMarin Pharma gets DOJ subpoena on certain drug testing programs (Reuters)
Feb-23-24 04:29PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
12:33PM	BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2023 Earnings Call Transcript (Insider Monkey)
11:34AM	BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales (Zacks)
07:21AM	Q4 2023 Biomarin Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
05:43AM	20 Fastest Growing Biotech Companies in the US (Insider Monkey)
04:25AM	BioMarin preaches patience amid slow sales for hemophilia gene therapy (BioPharma Dive)
Feb-22-24 06:00PM	Here's What Key Metrics Tell Us About BioMarin (BMRN) Q4 Earnings (Zacks)
05:15PM	BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates (Zacks)
04:42PM	BioMarin Pharmaceutical Inc. (BMRN) Announces Record Financial Results for 2023 (GuruFocus.com)
04:23PM	BioMarin: Q4 Earnings Snapshot (Associated Press Finance)
04:03PM	BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024 (PR Newswire)
Feb-19-24 09:15AM	Seeking Clues to BioMarin (BMRN) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Feb-15-24 10:00AM	BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy? (Zacks)
01:10PM	Loading…
Feb-13-24 01:10PM	PRIMECAP Management Bolsters Stake in Biomarin Pharmaceutical Inc (GuruFocus.com)
Feb-08-24 04:10PM	7 Biotech Stocks Fighting Americas Deadliest Diseases (InvestorPlace)
08:00AM	BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET (PR Newswire)
Feb-07-24 05:21AM	3 No-Brainer Stocks to Buy With $200 Right Now (Motley Fool)
Feb-06-24 08:30AM	BioMarin to Present ROCTAVIAN (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress (PR Newswire)
Jan-24-24 11:21AM	Here's Why Investors May Bet on BioMarin (BMRN) Stock Now (Zacks)
Jan-23-24 08:00AM	Catalyst Pharmaceuticals: An Attractive Biopharma Bet (GuruFocus.com)
Jan-20-24 05:06AM	4 Marvelous Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Jan-15-24 09:45AM	BioMarin Pharmaceutical (BMRN) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Jan-10-24 06:16PM	If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names (InvestorPlace)
Jan-03-24 08:00AM	BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA (PR Newswire)
Dec-21-23 06:14AM	BioMarin strikes deal with Elliott, agrees to review business (BioPharma Dive)
Dec-20-23 05:08PM	BioMarin settles with Elliott, adds 3 independent directors (Reuters)
04:05PM	BioMarin Announces Governance Enhancements and Value Creation Initiatives (PR Newswire)
Dec-14-23 07:05PM	Insider Sell: EVP, Chief Legal Officer George Davis Sells 13,764 Shares of Biomarin ... (GuruFocus.com)
Dec-05-23 11:01AM	Billionaire Louis Bacons 10 Stock Picks with Huge Upside Potential (Insider Monkey)
Dec-02-23 05:06AM	4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Dec-01-23 11:31AM	Why Is BioMarin (BMRN) Up 14.3% Since Last Earnings Report? (Zacks)
Nov-29-23 09:13PM	Elfun Trusts Sheds Qualcomm in Q3, Embraces New Holdings (GuruFocus.com)
06:30AM	BioMarin secures hemophilia gene therapy coverage in Germany (BioPharma Dive)
Nov-28-23 11:09AM	BioMarin prices hemophilia gene therapy at nearly 29,000 euros per vial in Germany (Reuters)
08:30AM	BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany (PR Newswire)
Nov-16-23 08:47AM	3 Biotech Stocks Beating BioMarin Pharmaceutical (BMRN) (Entrepreneur: Stocks)
Nov-10-23 12:58AM	BioMarin gains on report Elliott has a stake: Insider trades & hedge funds weekly (Investing.com)
Nov-09-23 04:43PM	Under the Microscope: 3 Biotech Stocks Pioneering Tomorrows Cures (InvestorPlace)
03:49AM	Top 20 Drug Companies in the US by Revenue (Insider Monkey)
Nov-08-23 05:19AM	3 Promising Biotech Stocks Flying Under the Radar (InvestorPlace)
Nov-07-23 07:09PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research) +12.16%
05:07PM	BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake (Investor's Business Daily)
02:24PM	BMRN Stock Jumps 12% as Activist Elliott Targets BioMarin Pharmaceuticals (InvestorPlace)
Nov-06-23 07:20PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
Nov-04-23 05:06AM	4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Nov-03-23 01:23AM	The Biomarin Pharmaceutical Inc (BMRN) Company: A Short SWOT Analysis (GuruFocus.com)
Nov-02-23 05:02PM	BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.17%
12:17PM	BioMarin (BMRN) Q3 Earnings in Line, Sales Miss, '23 View Cut (Zacks)
08:44AM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
07:15AM	BioMarin to replace CEO Bienaimé with Genentech veteran (BioPharma Dive)
Nov-01-23 06:30PM	BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:55PM	Biomarin Pharmaceutical Inc (BMRN) Reports 15% Total Revenue Growth in Q3 2023 (GuruFocus.com)
05:02PM	BioMarin: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year (PR Newswire)
04:02PM	BioMarin Announces Retirement of Jean-Jacques Bienaim; Appoints Alexander Hardy President and Chief Executive Officer (PR Newswire)
Oct-27-23 07:15AM	The Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical (Zacks)
Oct-26-23 11:28AM	Biotech Stock Roundup: BMY's Q3 Results, PTCT Up on Deal, BEAM's Restructuring News (Zacks)
10:02AM	Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-25-23 10:02AM	BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-23-23 09:50AM	Pinterest upgraded, Salesforce downgraded: Wall Street's top analyst calls (The Fly)
Oct-20-23 04:20PM	UPDATE 2-BioMarin's dwarfism therapy gets FDA nod for expanded use (Reuters)
04:11PM	U.S. FDA approves expanded use of BioMarin's dwarfism therapy (Reuters)
04:05PM	U.S. Food and Drug Administration Approves BioMarin's VOXZOGO (vosoritide) for Children Under 5 Years with Achondroplasia (PR Newswire)
Oct-19-23 12:17PM	Elevance Health (ELV) Q3 Earnings Beat on Carelon Unit Strength (Zacks)
08:15AM	3 Under-the-Radar Biotech Stocks to Buy in 2023 (Motley Fool)
Oct-18-23 12:10PM	Why BioMarin (BMRN) Could Beat Earnings Estimates Again (Zacks)
Oct-17-23 08:30AM	BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET (PR Newswire)
Sep-23-23 05:06AM	4 Awe-Inspiring Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Sep-21-23 10:00AM	BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting (PR Newswire)
Sep-18-23 10:52AM	BioMarin's share prices fluctuate following Phase 3 clinical trial results (Investing.com)
09:55AM	Micron upgraded, PayPal downgraded: Wall Street's top analyst calls (The Fly)
Sep-15-23 12:50PM	Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? (Investor's Business Daily)
09:29AM	BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia (PR Newswire)
08:37AM	Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks (Investor's Business Daily)
Sep-11-23 08:30AM	BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York (PR Newswire)
Sep-06-23 08:30AM	BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th (PR Newswire)
Sep-05-23 08:30AM	BioMarin to Participate in Three Upcoming Investor Conferences (PR Newswire)
Sep-02-23 05:06AM	4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Sep-01-23 11:31AM	Why Is Seattle Genetics (SGEN) Up 6.5% Since Last Earnings Report? (Zacks)
Aug-31-23 11:31AM	Why Is Incyte (INCY) Down 0.7% Since Last Earnings Report? (Zacks)
Aug-30-23 04:05PM	BioMarin Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe (PR Newswire)
Aug-12-23 05:06AM	4 Unforgettable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Aug-01-23 01:37PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIENAIME JEAN JACQUES	Director	Apr 12 '24	Option Exercise	63.10	20,000	1,262,000	494,994	Apr 15 04:21 PM
BIENAIME JEAN JACQUES	Director	Apr 12 '24	Sale	91.26	20,000	1,825,200	474,994	Apr 15 04:21 PM
BIENAIME JEAN JACQUES	Director	Apr 11 '24	Option Exercise	63.10	20,000	1,262,000	494,994	Apr 15 04:21 PM
BIENAIME JEAN JACQUES	Director	Apr 11 '24	Sale	90.99	20,000	1,819,800	474,994	Apr 15 04:21 PM
Burkhart Erin	GVP, Chief Accounting Officer	Apr 10 '24	Sale	90.00	2,286	205,740	16,156	Apr 12 03:07 PM
Davis George Eric	EVP, Chief Legal Officer	Mar 28 '24	Sale	88.34	24,602	2,173,341	55,856	Apr 01 04:54 PM
Slamon Dennis	Director	Mar 18 '24	Option Exercise	79.70	10,000	797,000	40,809	Mar 20 05:13 PM
BIENAIME JEAN JACQUES	Director	Mar 06 '24	Sale	86.71	1,000	86,713	560,203	Mar 07 05:35 PM
FUCHS HENRY J	President, Worldwide R&D	Mar 05 '24	Sale	85.18	35,341	3,010,396	212,117	Mar 07 06:54 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Mar 05 '24	Sale	87.07	4,000	348,280	94,047	Mar 07 05:32 PM
BIENAIME JEAN JACQUES	Director	Mar 05 '24	Sale	85.51	1,000	85,510	561,203	Mar 07 05:35 PM
BIENAIME JEAN JACQUES	Director	Feb 27 '24	Sale	90.35	1,000	90,350	562,203	Feb 29 05:05 PM
BIENAIME JEAN JACQUES	Director	Feb 09 '24	Option Exercise	63.10	15,000	946,500	434,602	Feb 12 05:20 PM
BIENAIME JEAN JACQUES	Director	Feb 09 '24	Sale	88.28	15,000	1,324,200	419,602	Feb 12 05:20 PM
BIENAIME JEAN JACQUES	Director	Feb 08 '24	Option Exercise	63.10	15,000	946,500	434,602	Feb 12 05:20 PM
BIENAIME JEAN JACQUES	Director	Feb 08 '24	Sale	89.77	15,000	1,346,550	419,602	Feb 12 05:20 PM
BIENAIME JEAN JACQUES	Director	Jan 10 '24	Option Exercise	63.10	10,000	631,000	435,162	Jan 11 02:40 PM
BIENAIME JEAN JACQUES	Director	Jan 10 '24	Sale	96.38	10,000	963,800	425,162	Jan 11 02:40 PM
BIENAIME JEAN JACQUES	Director	Jan 09 '24	Option Exercise	63.10	10,000	631,000	435,162	Jan 11 02:40 PM
BIENAIME JEAN JACQUES	Director	Jan 09 '24	Sale	98.19	10,000	981,900	425,162	Jan 11 02:40 PM
BIENAIME JEAN JACQUES	Director	Dec 21 '23	Option Exercise	63.10	10,000	631,000	435,112	Dec 22 05:14 PM
BIENAIME JEAN JACQUES	Director	Dec 21 '23	Sale	93.99	10,000	939,900	425,112	Dec 22 05:14 PM
Davis George Eric	EVP, Chief Legal Officer	Dec 13 '23	Sale	95.30	13,764	1,311,709	55,710	Dec 14 06:18 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Aug 16 '23	Sale	90.00	5,000	450,000	60,804	Aug 17 03:57 PM
FUCHS HENRY J	President, Worldwide R&D	Aug 10 '23	Sale	90.43	12,000	1,085,111	176,187	Aug 11 01:59 PM
Guyer Charles Greg	EVP, Chief Technical Officer	Aug 09 '23	Sale	93.30	5,360	500,109	40,041	Aug 10 04:47 PM
Davis George Eric	EVP, Chief Legal Officer	Aug 08 '23	Sale	89.42	11,000	983,662	69,474	Aug 09 07:08 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Aug 08 '23	Sale	88.29	6,000	529,740	422,732	Aug 09 07:05 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Aug 07 '23	Sale	88.10	4,000	352,400	428,732	Aug 09 07:05 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 12 '23	Option Exercise	67.81	46,500	3,153,165	472,713	May 16 05:22 PM
MEIER RICHARD A	Director	May 12 '23	Option Exercise	67.81	8,500	576,385	117,494	May 17 06:14 PM
HERON ELAINE J	Director	May 12 '23	Option Exercise	67.81	8,500	576,385	94,068	May 17 06:14 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 11 '23	Option Exercise	67.81	30,000	2,034,300	456,213	May 15 04:58 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 11 '23	Sale	94.67	30,000	2,840,226	426,213	May 15 04:58 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 10 '23	Option Exercise	67.81	30,000	2,034,300	456,213	May 11 05:04 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 10 '23	Sale	94.85	30,000	2,845,397	426,213	May 11 05:04 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 09 '23	Option Exercise	67.81	30,000	2,034,300	456,213	May 11 05:04 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 09 '23	Sale	94.93	30,000	2,847,973	426,213	May 11 05:04 PM

Open in Screener

INCY

Incyte Corp.

Apr 23 • 04:00PM ET

51.65

Dollar change -0.27
Percentage change -0.52	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO VO USMV VUG IVV RSP IBB VOT VHT

Index	S&P 500	P/E	19.53	EPS (ttm)	2.64	Insider Own	1.20%	Shs Outstand	224.29M	Perf Week	-2.95%
Market Cap	11.60B	Forward P/E	9.77	EPS next Y	5.28	Insider Trans	-0.34%	Shs Float	221.84M	Perf Month	-9.35%
Income	597.60M	PEG	0.87	EPS next Q	0.83	Inst Own	98.87%	Short Float	3.63%	Perf Quarter	-16.52%
Sales	3.70B	P/S	3.14	EPS this Y	23.23%	Inst Trans	0.60%	Short Ratio	4.68	Perf Half Y	-6.31%
Book/sh	23.14	P/B	2.23	EPS next Y	21.63%	ROA	9.41%	Short Interest	8.06M	Perf Year	-30.75%
Cash/sh	16.28	P/C	3.17	EPS next 5Y	22.50%	ROE	12.50%	52W Range	50.27 - 75.74	Perf YTD	-17.74%
Dividend Est.	-	P/FCF	24.99	EPS past 5Y	38.99%	ROI	11.42%	52W High	-31.81%	Beta	0.69
Dividend TTM	-	Quick Ratio	3.69	Sales past 5Y	14.55%	Gross Margin	91.47%	52W Low	2.75%	ATR (14)	1.10
Dividend Ex-Date	-	Current Ratio	3.75	EPS Y/Y TTM	73.98%	Oper. Margin	17.64%	RSI (14)	21.61	Volatility	1.75% 1.88%
Employees	2524	Debt/Eq	0.01	Sales Y/Y TTM	8.87%	Profit Margin	16.17%	Recom	2.04	Target Price	73.69
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	602.37%	Payout	0.00%	Rel Volume	1.45	Prev Close	51.92
Sales Surprise	1.06%	EPS Surprise	-7.85%	Sales Q/Q	9.35%	Earnings	Apr 30 BMO	Avg Volume	1.72M	Price	51.65
SMA20	-5.81%	SMA50	-9.94%	SMA200	-13.02%	Trades		Volume	2,493,671	Change	-0.52%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-23-24	Initiated	Cantor Fitzgerald	Neutral
Feb-23-24	Initiated	Jefferies	Buy	$81
Feb-14-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-13-23	Upgrade	Leerink Partners	Market Perform → Outperform	$78
Dec-04-23	Upgrade	Guggenheim	Neutral → Buy	$86
Nov-21-23	Downgrade	Goldman	Buy → Neutral	$98 → $65
Jul-25-23	Initiated	Citigroup	Buy	$82
May-04-23	Downgrade	BofA Securities	Buy → Neutral	$84
Apr-10-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$81 → $79
Mar-24-23	Upgrade	SVB Securities	Underperform → Market Perform	$61
Jan-31-23	Initiated	Piper Sandler	Overweight	$100
Aug-03-22	Downgrade	Guggenheim	Buy → Neutral
Aug-03-22	Downgrade	Evercore ISI	Outperform → In-line	$90 → $78
Jul-28-22	Initiated	Wells Fargo	Equal Weight	$76
Feb-09-22	Downgrade	SVB Leerink	Mkt Perform → Underperform	$60 → $56
Jan-18-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$78 → $90
Nov-19-21	Initiated	BMO Capital Markets	Market Perform	$75
Jul-20-21	Upgrade	The Benchmark Company	Hold → Buy	$89
Feb-10-21	Downgrade	SVB Leerink	Mkt Perform → Underperform	$70
Jan-07-21	Initiated	Truist	Buy	$120

Show Previous Ratings

Apr-23-24 10:12AM	Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M (FierceBiotech.com)
10:01AM	Incyte (INCY) Earnings Expected to Grow: Should You Buy? (Zacks)
09:44AM	Incyte (INCY) to Report Q1 Earnings: What's in the Cards? (Zacks)
07:00AM	Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists (Business Wire)
Apr-15-24 05:30AM	Certain Biotech Investors Get an Early Look at Results. Is That Fair? (The Wall Street Journal)
08:00AM	Loading…
Apr-11-24 08:00AM	Incyte to Report First Quarter Financial Results (Business Wire)
Apr-06-24 08:56AM	Biotech Executive Who Bet on Rivals Stock Committed Insider Trading, Jury Says (The Wall Street Journal)
Apr-01-24 08:30AM	Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia (Business Wire)
08:30AM	CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia (GlobeNewswire)
Mar-31-24 11:53AM	12 Best S&P 500 Stocks To Buy According to Analysts (Insider Monkey)
Mar-29-24 04:30PM	Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-26-24 02:47PM	SEC Tests Insider-Trading Theory at Trial of Ex-Biotech Executive (Bloomberg)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-15-24 10:37AM	MorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 11:30AM	Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report? (Zacks)
08:18AM	Loading…
08:18AM	MacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-12-24 01:52PM	Incyte (INCY) Posts Positive Results on Opzelura From HS Study (Zacks)
Mar-11-24 01:02PM	Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead (InvestorPlace)
07:18AM	Incyte, itching for a piece of Dupixent's market, hits goals in midphase skin disease trial (FierceBiotech.com)
Mar-10-24 04:05PM	Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis (Business Wire)
04:05PM	Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura) in Patients with Mild-to-Moderate Hidradenitis Suppurativa (Business Wire)
Mar-07-24 03:00PM	3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise (InvestorPlace)
Mar-04-24 08:00AM	New Data from Incytes Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting (Business Wire)
Mar-03-24 08:29AM	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 10:19AM	Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients Lives through Generative AI (Business Wire)
07:30AM	Knight Therapeutics Announces Launch of Minjuvi in Brazil (GlobeNewswire)
Feb-28-24 01:10PM	Q4 2023 Syndax Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 04:08PM	Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease (Business Wire)
Feb-26-24 03:20PM	7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff (InvestorPlace)
Feb-21-24 04:50PM	Exit Now! 3 Biotech Stocks to Sell in February 2024 (InvestorPlace)
08:00AM	Loading…
Feb-15-24 08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
Feb-14-24 09:32AM	Incyte Corporation (NASDAQ:INCY) Q4 2023 Earnings Call Transcript (Insider Monkey)
01:15AM	Q4 2023 Incyte Corp Earnings Call (Thomson Reuters StreetEvents)
12:12AM	Decoding Incyte Corp (INCY): A Strategic SWOT Insight (GuruFocus.com)
Feb-13-24 05:43PM	Analyst Report: Incyte Corporation (Morningstar Research)
11:37AM	Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates (Zacks)
09:30AM	Here's What Key Metrics Tell Us About Incyte (INCY) Q4 Earnings (Zacks)
08:26AM	Incyte misses quarterly profit estimates due to higher costs (Reuters)
08:25AM	Incyte (INCY) Lags Q4 Earnings and Revenue Estimates (Zacks)
07:38AM	Incyte Corp (INCY) Reports Solid Growth in 2023, Sets Sights on Future Pipeline Expansion (GuruFocus.com)
07:35AM	Incyte Q4 Adj EPS Misses Estimates, But Revenues Top (RTT News)
07:34AM	Incyte: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities (Business Wire)
Feb-09-24 11:03AM	Incyte (INCY) to Report Q4 Earnings: What's in the Cards? (Zacks)
09:15AM	Ahead of Incyte (INCY) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
Feb-07-24 08:55AM	Pancreatic Cancer Treatments Poised for Major Advances in 2024 (PR Newswire)
Feb-06-24 04:30AM	MorphoSys to sell to Novartis for $2.9B, offload cancer drug to Incyte (BioPharma Dive)
Feb-05-24 06:54PM	Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion (Investor's Business Daily)
04:46PM	Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi) (Business Wire)
Jan-31-24 07:33PM	Analyst Report: Incyte Corporation (Morningstar Research)
Jan-30-24 11:07AM	Agilent, Incyte to partner on companion diagnostics (MedTech Dive)
Jan-26-24 09:12AM	Incyte (INCY) Banks on Opzelura as Jakafi Faces Competition (Zacks)
Jan-24-24 08:39AM	Incyte vets, with phase 1 within reach, raise $102M for new biotech to create better PARP, PI3K drugs (FierceBiotech.com)
Jan-23-24 08:00AM	Incyte to Report Fourth Quarter and Year-End 2023 Financial Results (Business Wire)
Jan-18-24 04:00PM	3 Pharma Stocks Could Be the Pills Your Portfolio Needs (InvestorPlace)
Jan-08-24 08:30AM	Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-06-24 11:02AM	EVP & Chief Medical Officer Steven Stein Sells Shares of Incyte Corp (INCY) (GuruFocus.com)
Jan-02-24 07:19PM	Analyst Report: Incyte Corporation (Morningstar Research)
Dec-20-23 01:50PM	12 Most Promising Gene Editing Stocks According to Hedge Funds (Insider Monkey)
Dec-19-23 11:41AM	13 Most Promising Healthcare Stocks According to Analysts (Insider Monkey)
Dec-15-23 02:30PM	The 3 Most Undervalued Biotech Stocks to Buy in December (InvestorPlace)
Dec-12-23 12:46PM	Incyte Stock Is the S&P 500s Top Performer. Heres Why Its Surging. (Barrons.com) +8.45%
08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
Dec-10-23 05:00PM	Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease (Business Wire)
Dec-05-23 10:32AM	Incyte's Bullish Outlook: A Surprising Strength You Shouldn't Overlook (GuruFocus.com)
Nov-30-23 11:31AM	Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report? (Zacks)
Nov-16-23 12:17PM	5 Best Debt Free Stocks To Buy (Insider Monkey)
Nov-13-23 09:50PM	Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks (Insider Monkey)
Nov-12-23 08:18AM	3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024 (InvestorPlace)
Nov-09-23 10:01PM	7 Underappreciated Biotech Stocks to Pick Up on the Cheap (InvestorPlace)
Nov-02-23 09:00AM	Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting (Business Wire)
Nov-01-23 12:32PM	Incyte Corporation (NASDAQ:INCY) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-31-23 09:52PM	Analyst Report: Incyte Corporation (Morningstar Research)
12:14PM	Incyte (INCY) Beats on Q3 Earnings, Misses Revenue Estimates (Zacks)
09:36AM	Drugmaker Incyte's quarterly profit beats on lower costs (Reuters)
09:30AM	Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:43AM	Incyte Corp (INCY) Reports 12% Y/Y Increase in Q3'23 Total Revenues (GuruFocus.com)
08:15AM	Incyte (INCY) Surpasses Q3 Earnings Estimates (Zacks)
07:09AM	Incyte: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs (Business Wire)
Oct-30-23 11:37AM	Drug, Biotech Stocks' Q3 Earnings Due on Oct 31: AMGN, PFE, INCY (Zacks)
Oct-27-23 11:36AM	Incyte (INCY) to Report Q3 Earnings: What's in the Cards? (Zacks)
08:00AM	Science Magazine Recognizes Incyte as #2 "Top Employer" of 2023 (Business Wire)
Oct-25-23 10:02AM	Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-20-23 12:04PM	5 Cheap Biotech Stocks Smart Investors Are Piling Into (Insider Monkey)
Oct-18-23 08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
Oct-16-23 08:00AM	Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023 (Business Wire)
07:30AM	Knight Therapeutics Announces CMED Price Approval of Minjuvi (tafasitamab) in Brazil (GlobeNewswire)
Oct-13-23 12:44PM	Incyte (INCY) Stock Plummets 29.6% Year to Date: Here's Why (Zacks)
10:30AM	Incyte Announces New Data for Ruxolitinib Cream (Opzelura) in Children with Atopic Dermatitis (Business Wire)
08:00AM	Data From Incytes Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) (Business Wire)
Oct-12-23 11:29AM	Incyte (INCY) Posts Upbeat Data From Phase II Vitiligo Study (Zacks)
09:00AM	Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032 (GlobeNewswire)
Oct-11-23 10:30AM	New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients (Business Wire)
09:15AM	Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity (Business Wire)
08:15AM	Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo (Business Wire)
Oct-10-23 04:45PM	Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil (GlobeNewswire)
08:00AM	Incyte to Report Third Quarter Financial Results (Business Wire)
Sep-29-23 01:43PM	Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress (Business Wire)
Sep-26-23 12:33PM	Unveiling Incyte (INCY)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stein Steven H	EVP & Chief Medical Officer	Jan 03 '24	Sale	65.51	7,365	482,481	90,218	Jan 05 12:27 PM
Iyengar Vijay K	EVP, GMAPPS	Jan 02 '24	Sale	65.00	657	42,705	43,412	Jan 04 01:05 PM
Tray Thomas	Principal Accounting Officer	Dec 13 '23	Sale	62.37	1,067	66,549	23,436	Dec 14 02:11 PM
Tray Thomas	Principal Accounting Officer	Dec 12 '23	Sale	57.36	210	12,046	24,503	Dec 14 02:11 PM
SWAIN PAULA J	EVP, Human Resources	Sep 01 '23	Sale	65.13	8,449	550,283	77,530	Sep 06 04:00 PM
Stein Steven H	EVP & Chief Medical Officer	Aug 01 '23	Sale	63.28	21,511	1,361,216	97,583	Aug 03 04:00 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

BMRN

Biomarin Pharmaceutical Inc.

INCY

Incyte Corp.

Upgrade your FINVIZ experience